EUVIMEDEUVIMED entdecken
LeserbriefKommentarOpen Access · CC BY-NC 4.0

Comments on “Prevalence, patient characteristics and outcomes of high-dose upadacitinib in inflammatory bowel disease”

Aliza Altaf iD, Fiza Memon iD, Lavish Kumar

Therapeutic Advances in Gastroenterology · 2026-07 · 19

DOI: 10.1177/17562848261465254 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Therapeutic Advances in Gastroenterology, online erschienen am 02.07.2026. Verfasst von Aliza Altaf und 2 weiteren Autor:innen. Beteiligte Einrichtung: Departement of Medicine, Peoples University of Medical and Health Science for Women, Nawabshah, Sindh 67450, Pakistan. Die Arbeit nennt 3 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

inflammation. With mucosal healing becoming an important therapeutic goal in current management of inflammatory bowel disease, sole dependence on clinical response may overestimate the actual effectiveness of high-dose upadacitinib. A more detailed discussion of this discordance would have improved interpretation of the study findings and provided better insight into the long-term disease-modifying potential of high-dose maintenance therapy.

Schlagwörter

Stichwörter der Autor:innen

crohn’s diseasehigh-doseinflammatory bowel diseaseulcerative colitisupadacitinib

Autor:innen und Institutionen

  • Departement of Medicine, Peoples University of Medical and Health Science for Women, Nawabshah, Sindh 67450, Pakistan.
  • Departement of Medicine, Liaquat University of Medical and Health Sciences, Jamshoro, Sindh, Pakistan.

ORCID-Profile: Aliza Altaf, Fiza Memon

Zitieren

APA

Altaf, A., Memon, F., & Kumar, L. (2026). Comments on “Prevalence, patient characteristics and outcomes of high-dose upadacitinib in inflammatory bowel disease”. Therapeutic Advances in Gastroenterology, 19. https://doi.org/10.1177/17562848261465254

Vancouver

Altaf A, Memon F, Kumar L. Comments on “Prevalence, patient characteristics and outcomes of high-dose upadacitinib in inflammatory bowel disease”. Therapeutic Advances in Gastroenterology. 2026;19. doi:10.1177/17562848261465254

BibTeX
@article{Altaf2026,
  author = {Altaf, Aliza and Memon, Fiza and Kumar, Lavish},
  title = {Comments on “Prevalence, patient characteristics and outcomes of high-dose upadacitinib in inflammatory bowel disease”},
  journal = {Therapeutic Advances in Gastroenterology},
  year = {2026},
  volume = {19},
  doi = {10.1177/17562848261465254}
}
Kostenlos starten →